Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member
Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member
STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and pain, today announced that Professor Jan Lundberg has been elected as a new board member at the company's annual general meeting in 2024.
瑞典斯德哥爾摩/ACCESSWIRE/2024年5月15日/AlzeCure Pharma（STO: ALZCUR）（FRA: AC6）專注於阿爾茨海默氏病和疼痛的中樞神經系統疾病候選藥物的製藥公司AlzeCure Pharma AB今天宣佈，揚·倫德伯格教授在公司2024年的年度股東大會上當選爲新的董事會成員。
Professor Jan Lundberg has more than 25 years of experience from leading positions in global pharmaceutical companies, including as global head of research at Astra and then AstraZeneca (1996 - 2009) and global head of research and development at Eli Lilly (2010 - 2018). He has led the development of more than 200 drug candidates, including Alzheimer's and pain, with 30 approved products in several therapeutic areas. Furthermore, Dr. Lundberg co-founded the medtech company Aerocrine, which was later acquired by British Circassia Pharmaceuticals for SEK 1.78 billion in 2015.
揚·倫德伯格教授在全球製藥公司的領導職位上擁有超過25年的經驗，包括先後在阿斯利康和阿斯利康擔任全球研究主管（1996年至2009年）和禮來全球研發主管（2010-2018年）。他領導了包括阿爾茨海默氏症和疼痛症在內的200多種候選藥物的開發，在多個治療領域有30種獲批准的產品。此外，倫德伯格博士與他人共同創立了醫療科技公司Aerocrine，該公司後來在2015年被英國切爾卡西亞製藥公司以17.8億瑞典克朗的價格收購。
Before joining Astra, Dr. Lundberg was professor of pharmacology at the Karolinska Institute in Sweden, where he also received his PhD. He also studied medicine at the University of Gothenburg for four years and his research has resulted in over 500 publications in peer-reviewed scientific journals.
在加入阿斯利康之前，倫德伯格博士曾在瑞典卡羅林斯卡學院擔任藥理學教授，並獲得了博士學位。他還在哥德堡大學學習了四年的醫學，他的研究已在同行評審的科學期刊上發表了500多篇文章。
Dr. Lundberg is also an honorary doctorate at the Faculty of Pharmacology at Uppsala University, Sweden and has received both the Fernström and Jahre prizes. Over the years, he has also been active in several international authority committees. He is currently a board member of several different pharmaceutical and biotechnology companies, and his extensive experience in research and development with a strong interest in central nervous system diseases will be a great asset to AlzeCure.
倫德伯格博士還是瑞典烏普薩拉大學藥理學院的榮譽博士學位，並獲得了 Fernstrom 和 Jahre 獎。多年來，他還活躍於多個國際權威委員會。他目前是幾家不同的製藥和生物技術公司的董事會成員，他在研發方面的豐富經驗以及對中樞神經系統疾病的濃厚興趣將是AlzeCure的寶貴資產。
"AlzeCure has a fantastically exciting and promising project portfolio in areas of very high medical need and in fields that I worked with. I am happy to be able to join the company in this exciting development phase and to contribute to the company's continued success," said Dr. Jan Lundberg.
“在醫療需求非常高的領域和我合作的領域，AlzeCure擁有非常令人興奮和前景廣闊的項目組合。我很高興能夠在這個激動人心的發展階段加入公司，爲公司的持續成功做出貢獻。” 揚·倫德伯格博士說。
"We are incredibly grateful and happy that Jan Lundberg has been elected a board member, and we are convinced that his experience and knowledge will make a very positive contribution to our continued future successful development," said Martin Jönsson, CEO of AlzeCure Pharma.
Alzecure Pharma首席執行官馬丁·瓊森表示：“揚·倫德伯格當選爲董事會成員，我們非常感激和高興，我們堅信他的經驗和知識將爲我們未來的持續成功發展做出非常積極的貢獻。”
For more information, please contact
欲了解更多信息，請聯繫
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
首席執行官馬丁·瓊森
電話：+46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
關於 AlzeCure Pharma AB（publ）
AlzeCure is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore, Alzstatin and Painless.
AlzeCure是一家瑞典制藥公司，致力於開發新的創新藥物療法，用於治療影響中樞神經系統的嚴重疾病和病症，例如阿爾茨海默氏病和疼痛，目前可用的治療適應症非常有限。該公司在納斯達克第一北方成長市場上市，並正在基於三個研究平台開發幾種平行候選藥物：NeuroRestore、Alzstatin和Painless。
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease, as well as for depression treatment. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions, alternatively partnership, with other pharmaceutical companies.
NeuroRestore由兩種有症狀的候選藥物組成，其獨特的作用機制允許多種適應症，包括阿爾茨海默氏病，以及與創傷性腦損傷、睡眠呼吸暫停和帕金森氏病相關的認知障礙，以及抑鬱症的治療。Alzstatin平台專注於開發用於阿爾茨海默病早期治療的疾病改善和預防候選藥物，包括兩種候選藥物。Painless是該公司在疼痛領域的研究平台，包含兩個項目：ACD440，這是治療神經性疼痛的臨床開發階段的候選藥物，以及針對骨關節炎等疾病的嚴重疼痛的TRKA-NAM。AlzeCure的目標是通過早期臨床階段的臨床前研究和開發來開展自己的項目，並不斷致力於業務發展，以尋找合適的外包解決方案，或者與其他製藥公司建立合作伙伴關係。
FNCA Sweden AB is the company's Certified Adviser. For more information, please visit .
FNCA Sweden AB是該公司的認證顧問。欲了解更多信息，請訪問。
Image Attachments
圖像附件
Jan Lundberg
揚·倫德伯格
Attachments
附件
Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg elected as a new board member
禮來公司和阿斯利康前研究主管揚·倫德伯格博士當選爲新的董事會成員
SOURCE: AlzeCure Pharma
來源：AlzeCure Pharma
譯文內容由第三人軟體翻譯。